

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT TECHNICAL COOPERATION AGREEMENT WITH GEUDER ON THE SOLUTION OF PHACOEMULSIFICATION AND VITRECTOMY SURGERY

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business developments of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, Gaush Tech Ltd.* (深圳高視科技有限公司) (“**Gaush Tech**”), a wholly-owned subsidiary of the Company, has recently signed a technology transfer, development and commercialization agreement with Geuder AG (“**Geuder**”), an important upstream partner of the Group in Germany, with an aim to introduce the world’s leading technology related to the phacoemulsification and vitrectomy surgery system (including equipment and supporting consumables), carry out technology localization, redevelopment and manufacturing in the Shenzhen base of the Group, and commercialize it to specific markets around the world.

The phacoemulsification and vitrectomy surgery system (including equipment and supporting consumables) introduced in this cooperation is mainly used for the treatment of cataract and vitreoretinal diseases. Cataract is a leading cause of blindness in the world. According to the statistics of the Chinese Ophthalmological Society, the incidence of cataract in people between 60 and 89 years old in China is 80%, and the incidence of cataract in people over 90 years old is more than 90%. With the aging of the Chinese population, the number of cataract patients will continue to increase, and the number of phacoemulsification operations will show a long-term growth trend. The main surgical method for vitreoretinal disease is vitrectomy (or VT for short), which is a general term for a major category of fundus (retina) surgery. Vitreous surgery is the second most important type of eye surgery in eye treatment centers in developed countries, only second to cataract extraction and intraocular lens implantation. Featuring long operation time and high difficulty in actual operation, it is a major ophthalmic surgery. Whether it is phacoemulsification surgery or vitrectomy, advanced surgical equipment and supporting consumables are important guarantees for the success of surgery.

The technological barrier of the Phaco-Vitrectomy All-in-One machine is high. At present, the demand of China's Phaco-Vitrectomy All-in-One machine market relies on imports, with no domestic equipment on the market for the time being. Geuder, Gaush Tech's partner for this technology introduction and commercialization, has been committed to innovative solutions in the field of phacoemulsification and vitrectomy for decades. The cooperation between the two parties is on the basis of "Technology Transfer Fee + Sharing of Future Sales Revenue", covering products such as phacoemulsification equipment, Phaco-Vitrectomy All-in-One machine, and various ancillary consumables. This further enriches the Group's ophthalmic surgical product portfolio and better provides product solutions to customers. Furthermore, following the successful establishment of its own research and development center and mergers and acquisitions both domestically and overseas, the Group will further strengthen its research and development and production capabilities and the diversified foundation of its own products through technology introduction and redevelopment.

ABOUT GEUDER

Geuder, founded in 1951 in Heidelberg, Germany, is a leading full-service company manufacturing ophthalmic products in the world. Up to now, Geuder has produced over 3,000 ophthalmic products for clinical use in ophthalmology, which sold well in more than 100 countries around the world.

To the best knowledge of the Directors, Geuder is not a connected person of the Company (within the meaning of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) as of the date of this announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Gaush Meditech Ltd

Mr. Gao Tieta

Chairman and Executive Director

Hong Kong, September 9, 2024

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purposes only*